[General pharmacological studies on isepamicin sulfate (HAPA-B)]
- PMID: 3586327
[General pharmacological studies on isepamicin sulfate (HAPA-B)]
Abstract
General pharmacological properties of isepamicin sulfate (HAPA-B), a new aminoglycoside antibiotic, were studied in animals and the results obtained were summarized below. Intramuscular injections of HAPA-B at doses of 500 mg/kg inhibited the writing response induced by acetic acid, and at doses of 1,000 mg/kg, caused muscle relaxation, respiratory depression, suppression of spontaneous motor activity and prolongation of thiopental anesthesia. Anticonvulsive action and the effect on the rectal temperature were not observed. Intravenous Intravenous HAPA-B showed no significant effect on the general behavior and the function of the central nervous system at doses of 100 mg/kg. Intravenous injections of HAPA-B to anesthetized dogs resulted increases in the femoral arterial blood flow at doses of 12.5 mg/kg, decrease in the blood pressure and increase in the respiratory rate at doses of 25 mg/kg, and increase in the carotid arterial blood flow at doses of 50 mg/kg. Apparent changes were not recognized in the heart rate and electrocardiograms. In conscious rabbits, intravenous HAPA-B produced increases in the heart rate without significant changes of the blood pressure and electrocardiograms at doses of 100 mg/kg. Spontaneous beatings of isolated atria were depressed by HAPA-B in concentrations of 3 X 10(-4) to 10(-3) g/ml. The HAPA-B inhibited the gastric secretion at intramuscular doses of 500 mg/kg or intravenous doses of 100 mg/kg, and depressed charcoal transport through small intestine and the spontaneous movement of isolated ileum at intramuscular doses of 1,000 mg/kg and at concentrations of 3 X 10(-4) to 10(-3) g/ml, respectively. No irritative effect was found on the gastric mucous membrane. Intravenous HAPA-B inhibited the response of nictitating membrane to pre and post ganglionic stimulations of cervical sympathetic nerve at doses of 100 mg/kg. In in vitro test, HAPA-B inhibited nonspecifically the constrictive responses of trachea, aorta, stomach, ileum and vas deferens to various agonists in concentrations of 3 X 10(-4) to 10(-3) g/ml. Spontaneous movements of uteri of estrous or pregnant animals were depressed by HAPA-B at intravenous doses of 50 to 100 mg/kg and in in vitro at concentrations of 10(-4) to 3 X 10(-4) g/ml. Antidiuretic effect was also observed at intramuscular doses of 250 mg/kg. HAPA-B increased the length of the whole blood clotting time and raised the plasma glucose level at intramuscular doses of 1,000 mg/kg and inhibited the platelet aggregation induced by ADP in vitro at concentrations of 10(-3) g/ml.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
General pharmacology of recombinant human basic fibroblast growth factor.Arzneimittelforschung. 1996 Jul;46(7):727-39. Arzneimittelforschung. 1996. PMID: 8842346
-
[General pharmacology of T-3262, a new pyridonecarboxylic acid].Jpn J Antibiot. 1989 Apr;42(4):831-53. Jpn J Antibiot. 1989. PMID: 2769937 Japanese.
-
General pharmacological properties of the new vasodilator flosequinan.Arzneimittelforschung. 1992 Oct;42(10):1200-11. Arzneimittelforschung. 1992. PMID: 1472141
-
Pathophysiologic roles of prostaglandins and the action of aspirin-like drugs.South Med J. 1973 Jun;66(6):709-23. doi: 10.1097/00007611-197306000-00023. South Med J. 1973. PMID: 4575324 Review. No abstract available.
-
A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol.Gen Pharmacol. 1978;9(2):73-8. doi: 10.1016/0306-3623(78)90002-2. Gen Pharmacol. 1978. PMID: 350698 Review. No abstract available.